Contributions
Abstract: PB2120
Type: Publication Only
Background
Monoclonal gammopathies (MG) are heterogeneous diseases with focal lesions in the bone marrow (BM); therefore, analysis of biopsy specimen obtained from a single biopsy site in the BM may not always contain information about all pathological clones. In the case of MM, these subclones directly influence survival of patients and may not be present in the sampled BM. The so-called liquid biopsies (biopsies of peripheral blood) represent a real promise for these diseases since circulating molecules that are detectable in peripheral blood (PB) mirror the complex heterogeneity of MG and can serve as potential diagnostic, prognostic and predictive markers. So far, others and we showed that these molecules include cell-free DNA and non-coding RNA (ncRNA), especially microRNA (miRNA) and long non-coding RNA (lncRNA). LncRNA expression is tissue-specific and implicated in diverse biological functions, including physiological and pathological processes, including tumorigenesis. At the same time, it is known that these molecules circulate in body fluids but their potential as MG diagnostic markers has not been clarified yet.
Aims
We investigated lncRNA expression profiles in exosomal fraction of peripheral blood serum of newly diagnosed multiple myeloma (MM) patients, monoclonal gammopathy of undetermined significance (MGUS) patients in comparison to healthy donors (HD) to find out if circulating lncRNA may be used as diagnostic markers of MG.
Methods
We performed expression profiling of 84 lncRNA by a commercial lncRNA PCR Array, followed by validation of chosen lncRNA by quantitative real-time PCR on a cohort of 50 MM, 49 MGUS patients and 30 healthy donors.
Results
Our analysis revealed dysregulation of exosomal lncRNA PRINS in MM vs. HD with sensitivity of 80.8% and specificity of 76.9%; for exosomal PRINS in MGUS vs. HD, sensitivity was 83.3% and specificity 80.8%. Overall, expression of exosomal lncRNA PRINS distinguished MM and MGUS patients from HD with sensitivity of 84.9% and specificity of 83.3%.
Conclusion
Our study suggests a possible diagnostic role for exosomal lncRNA PRINS in monoclonal gammopathies patients.
Session topic: 13. Myeloma and other monoclonal gammopathies – Biology & Translational Research
Abstract: PB2120
Type: Publication Only
Background
Monoclonal gammopathies (MG) are heterogeneous diseases with focal lesions in the bone marrow (BM); therefore, analysis of biopsy specimen obtained from a single biopsy site in the BM may not always contain information about all pathological clones. In the case of MM, these subclones directly influence survival of patients and may not be present in the sampled BM. The so-called liquid biopsies (biopsies of peripheral blood) represent a real promise for these diseases since circulating molecules that are detectable in peripheral blood (PB) mirror the complex heterogeneity of MG and can serve as potential diagnostic, prognostic and predictive markers. So far, others and we showed that these molecules include cell-free DNA and non-coding RNA (ncRNA), especially microRNA (miRNA) and long non-coding RNA (lncRNA). LncRNA expression is tissue-specific and implicated in diverse biological functions, including physiological and pathological processes, including tumorigenesis. At the same time, it is known that these molecules circulate in body fluids but their potential as MG diagnostic markers has not been clarified yet.
Aims
We investigated lncRNA expression profiles in exosomal fraction of peripheral blood serum of newly diagnosed multiple myeloma (MM) patients, monoclonal gammopathy of undetermined significance (MGUS) patients in comparison to healthy donors (HD) to find out if circulating lncRNA may be used as diagnostic markers of MG.
Methods
We performed expression profiling of 84 lncRNA by a commercial lncRNA PCR Array, followed by validation of chosen lncRNA by quantitative real-time PCR on a cohort of 50 MM, 49 MGUS patients and 30 healthy donors.
Results
Our analysis revealed dysregulation of exosomal lncRNA PRINS in MM vs. HD with sensitivity of 80.8% and specificity of 76.9%; for exosomal PRINS in MGUS vs. HD, sensitivity was 83.3% and specificity 80.8%. Overall, expression of exosomal lncRNA PRINS distinguished MM and MGUS patients from HD with sensitivity of 84.9% and specificity of 83.3%.
Conclusion
Our study suggests a possible diagnostic role for exosomal lncRNA PRINS in monoclonal gammopathies patients.
Session topic: 13. Myeloma and other monoclonal gammopathies – Biology & Translational Research